

E

E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

• Email: editor@ijfmr.com

# Prevalence and Antibiotic Susceptibility of Urinary Tract Infections in Diabetic and Non-Diabetic Individuals: A Prospective Study

### Mr. Kartik Rana<sup>1</sup>, Mrs. Shweta Thusoo<sup>2</sup>

<sup>1</sup>Department Of Medical Laboratory Technology, Sushant University <sup>2</sup>Program Coordinator & Assistant Professor Department of Medical Laboratory Technology, Sushant University

#### ABSTRACT

**Background & Objectives:** The increasing prevalence of Diabetes mellitus is one of today's major emerging health problems in most developing countries like India. In many studies it is discovered that diabetic individuals are more prone to catching UTIs. And with emergence of drug resistant uropathogens the treatment of UTI with empirical drugs is not as effective. So, the goal of this study is to determine the prevalence and etiology of uropathogens causing UTIs in diabetics. Comparative study of etiological distribution and overall susceptibility pattern among diabetic and non-diabetic individuals.

**Materials and Methods:** A cross-sectional prospective study on 220 individuals was carried out from March to April 2023 to determine the spectrum of pathogens causing urinary tract infections and to determine their antibiotic susceptibility profile. Primary cultures were done on standard Mcconkey and sheep blood agar to determine growth and selecting bacterial isolates. Identification & AST was done with the Vitek2 system and Kirby Bauer's disc diffusion method on Muller Hinton Agar.

**Results:** Among the 220 samples tested 150 samples showed significant bacteriuria. Of 48 diabetic individuals 36 (75%) were found positive for UTI's, prevalence of UTI was more common in females in comparison to males in both diabetic and normal population. In this study, 135 (61.4%) gram negative bacilli and 12 (5.5%) gram positive cocci were isolated, among which E.coli (52.7%) was the most common uropathogen followed by Klebsiella (25.3%), Pseudomonas (6.7%), Citrobacter (3.3%), Acinetobacter (2%) and Proteus (2%). Among the gram positive organisms, Enterococcus (5.3%) was the highest followed by Staphylococcus spp. (2.7%). Candida isolates were detected in 3 cases (2%).

Meropenem (87.6%) was the most susceptible antibiotic for gram negative bacilli followed by Netilmycin (87.6%), Imipenem (82.5%), Amikacin (82%) and Fosfomycin (81%). For the gram positive organisms Imipenem, Nitrofurantoin, Gentamicin, Vancomycin and Linezolid were all found to be highly susceptible antibiotics followed by Ciprofloxacin, Rifampin. For gram positive organisms Ampicillin, Ampicillin sulbactam, Ticarcillin clavulanic, Minocycline and for the gram negative organisms Ciprofloxacin, Ampicillin sulbactam, Doxycycline were found to be highly resistant.

**Conclusion:** E.coli is still the most common uropathogen in both diabetic and normal populations. Sensitivity to meropenem, imipenem, amikacin and fosfomycin are still highly retained and may be prescribed for complicated UTI. Routine monitoring of drug resistance patterns will help to identify the resistance trends regionally. This will help in the empirical treatment of UTIs to the clinicians.



Keywords: UTI, Uropathogens, Diabetes, Antibiotic susceptibility, Resistance, Sensitivity, Vitek2.

#### INTRODUCTION

Diabetes mellitus (DM) is a metabolic syndrome usually characterized by abnormally elevated levels of blood glucose. It is defined by deficiency of insulin secretion by pancreas or inability of the body to utilize insulin. Increasing prevalence of diabetes is an alarming situation throughout the world and is a serious health problem, in most developing countries. In many studies it is concluded that individuals with DM show higher prevalence to many infectious diseases[6,7,26].

Poor control over diabetes, impaired renal function and nonspecific or specific immunity have not been shown to be substantial contributors to the increased occurrence of morbidity of UTI among patients with diabetes. Hyperglycemia by itself alone does not provide enough evidence to be causing predictable increase in uropathogens in individuals with DM.[11]

Urinary tract infections (UTI) are the one of the most common infections after the infections of the respiratory tract. The symptoms of UTI may vary from mild asymptomatic cystitis to pyelonephritis and septicemia[17,21]. Most of the research done in recent years conclude that there is clinical evidence pointing to the higher prevalence of UTIs among individuals with DM[19,25]. And has a higher risk factor to evolve into complicated or serious conditions.

UTI is the second most common clinical indication that employs use of empirical antibiotics for treatment. And since hyperglycemia and hypertension are major risk factors for complicated UTI. So, diabetic individuals are found to be at a higher risk to develop serious bacteriuria[9,14].

#### Pathogenesis and etiology of UTI

Urinary tract infection (UTI) is a disease in which microbial growth in the urinary tract causes bacteriuria and inflammation in the urinary tract. The urinary tract consists of kidneys, uterus, bladder, and urethra. UTI can cause inflammation of the urethra known as urethritis, inflammation of kidney nephrons called pyelonephritis, and inflammation of the bladder called cystitis[1,5].

Symptomatic infection of the bladder due to bacteriuria is called cystitis and its symptoms includes; dysuria, hematuria, pyuria, and continuous urge to urinate. Infection of the upper urinary tract and kidneys is called pyelonephritis. Symptoms usually include fever, nausea, vomiting, pyuria, and is confirmed by the finding presence of significant bacteriuria in urinalysis and urine culture in case along with these symptoms[3,13].

Asymptomatic UTI is defined with the presence of significant bacteriuria without the symptoms of an acute urinary tract infection. Asymptomatic bacteriuria is quite common in poorly controlled diabetic individuals commonly of a complication called diabetic nephropathy in which due to continuous level of elevated blood glucose kidney stats filtering small amount of glucose along with other waste resulting in presence of glucose in urine known as glycosuria.

UTI are most common bacterial infections in both males and females, but it is seen more frequently in females[10,12]. There are many routes by which uropathogens can invade and spread within the urinary tract, but the ascending route is the most common site for bacteria to enter the body. In the ascending route pathogenic bacteria ascend from the perineum and rectum to enter the urinary tract causing bacterial infections.. In an uncomplicated UTI usually only the bladder is involved. And when the bacteria invades the mucosal wall of the bladder, it causes an inflammatory reaction called cystitis[11,18,21].

Asymptomatic UTIs are commonly treated with different broad-spectrum empirical antibiotics. But the emergence of antibiotic resistant bacteria is a major global public health problem in both nosocomial and



community-acquired infections[1,3,6]. The problem is even more challenging in most developing countries with low socio-economic conditions, because of high prevalence of cases, irresponsible uses of antibiotics, with poor hygiene and infection prevention practices[7,15].

#### **RATIONALE OF THE STUDY**

So, in view of the increasing antibiotic resistance, regular monitoring of resistance patterns of uropathogen is necessary to improve use of empirical antibiotics to ensure appropriate treatment. And to do that current local knowledge of the organisms that cause UTI and their antibiotic susceptibility testing is necessary.

#### **Objectives of study**

- To determine the prevalence of UTI cases in diabetic and non-diabetic individuals.
- To study the antimicrobial susceptibility patterns of underlying uropathogens.
- Comparative study of etiological distribution and overall susceptibility pattern among diabetic and non-diabetic individuals.

#### LITERATURE REVIEW

Most of the research done in recent years conclude that there is clinical evidence pointing to the higher prevalence of infectious diseases like UTI's among individuals with DM. Asymptomatic bacteriuria can be defined as presence of bacteria in the urine with absence of urinary infection symptoms, a common clinical finding that often warrants a decision about whether to initiate antimicrobial therapy. There are few indications for treatment of asymptomatic bacteriuria with commonly used empirical drugs, but using inappropriate drugs for treatment contributes to the development of antimicrobial resistance[10,15].

From recent studies around the world, the resistance rate of various drugs is different for different regions of the world which is suspected to be due to availability of some drugs in certain regions. Since the use of empirical drugs is concerned with resistance rates of uropathogens knowledge of resistance patterns is important to reduce the risk of further development of drug resistance bacteria. Resistance rate of 20 % can be considered an acceptable limit for use of empirical drugs for treatment of UTIs[3,13].

UTI is caused by both GNB & GPC. However, according to most studies, commonly encountered bacteria are Gram negative in which E. coli is found to be the most common bacterial uropathogen worldwide. E.coli being the predominant aetiological agent in community practice[1,11]. Other bacterial agents include species of Klebsiella, Enterobacter, Proteus, Pseudomonas, Staphylococcus, Streptococcus and Enterococcus faecalis. As is evident from the results, this study demonstrated E coli to be the predominant aetiological agent (44.96%) amongst the gram negative bacilli and Staphylococcus aureus amongst the gram positive bacteria (92.3%) as the causative agents of UTI The isolates of most of the species exhibited a high rate of resistance to Ampicillin, Co-trimoxazole, Cefozolin, Norfloxacin and Nitrofurantoin. Resistance to antibiotics develops due to its frequent misuse[4].

Though some studies indicate that there's not much significance, the difference in resistance of the uropathogens to the antibiotics was found similar in patients with and without DM. The Pseudomonas resistance to ciprofloxacin was stated to be very high but at a similar rate in patients with and without DM[7].

#### METHODOLOGY

#### **Study Type and Population**

A cross-sectional prospective study was carried out for 2 months in the year 2023, from March to April



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

2023. Urine samples of a total 220 individuals were taken at random from the Microbiology department and were analyzed for this study.

Screening of diabetic individuals was done by taking measures of their glycosylated hemoglobin (HbA1c) levels. All samples were cultured to obtain isolates for identification and sensitivity testing.

#### **Inclusion criteria:**

Samples from all patients with a presumptive case of UTI were included in the study. Individuals having HbA1c level of  $\geq$  7 were considered as diabetic. Of all 220 individuals in study 48 (21.8%) were found diabetic of which there were 22 males and 26 females.(As shown in table1).

#### Inoculation of primary isolation culture media

The urine samples were processed using standard microbiological procedures. The specimens were directly inoculated on dried media plates of McConkey and Sheep Blood agar, by standard sterile nichrome loop streaking method and incubated at 37°C for 24 hr and 48 hr for negative cases. A growth of  $\geq 10^5$  colony forming units/mL was considered as significant bacteriuria causing UTIs.

<b>I</b>		8
Distribution of Population with		
gender	Male	Female
Diabetic	22	26
Non-diabetic	79	93

### Table1: Distribution of Population with gender.




Fig 1: Distribution of diabetic population with gender

#### Identification of isolates and determination of antimicrobial susceptibility

Primary identification was by reading the shape, size and characteristics of bacterial colonies cultured on the Macconkey and sheep blood agar plates. And biochemical tests like catalase, coagulase and oxidase.



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

Identification of bacterial species and the antibiotic susceptibility testing of both Gram-positive and Gramnegative isolates were determined with the automated VITEK 2 system (bioMérieux, France) using GN, GP and AST cards. The VITEK 2 system is a fully automated system for bacterial identification and antibiotic susceptibility testing. The system detects bacterial growth and metabolic changes in the microwells of plastic cards using advanced colorimetry based technology.

GN ID cards were used for the identification and AST-GN 405 cards for susceptibility testing of Gramnegative bacteria. While the GP ID cards were used for the identification and AST-GP 628 cards for susceptibility testing of Gram-positive bacteria. Every card contains one positive control well with no antibiotic (growth-promoting broth only) and multiple wells with increasing concentrations of various antibiotics in the broth. Growth in the control well shows that the test isolate is viable and appropriate for drug susceptibility testing. MIC is determined by comparing the growth of the patient isolate to the growth of isolates with known MIC.

A test tube containing the bacterial suspension in saline solution was placed into a rack (cassette) and the identification card was placed in the neighboring slot while placing another transfer tube corresponding to the suspension tube. All card types were automatically incubated at  $35.5 \pm 1.0$  °C. Final identification results were obtained in approximately 12-18 hrs.

#### Antibiotics used for sensitivity testing of GNB in AST-GN405 cards:

Amikacin, Augmentin, Azteronam ,Ampicillin Sulbactam, Cefepime, Cefoperazone sulbactam, Cefepime Tazobactam, Ceftriaxome, Cefuroxime, Ciprofloxacin, Doripenem, Doxycycline, Ticareillin Clavuanic, Gentamicin, Imipenam, Ertapenem, Co-Trimoxazole, Levofloxacin, Minocycline, Meropenam, Netilmicin, Nitrofurantoin, Piperacillin Tazobactam, Fosfomycin, Colistin.

Antibiotics used for sensitivity testing of GPC in AST-GP 628 cards:

Ampicillin, Augmentin, Amoxicillin, Ampicillin Sulbactam, Ciprofloxacin, Rifampin Doxycycline, Teicoplanin, Ticarcillin clavulanic, Gentamicin, Imipenam, Levofloxacin, Minocycline, Nitrofurantoin, Daptomycine, Penicillin-g, Vancomycin, Linezolid, Piperacillin-tazobactam, Tetracycline.

Manual sensitivity testing using Kirby Bauer's disc diffusion method on Muller Hinton Agar was also employed for some antibiotics to serve as comparison for AST data from the Vitek2 system. ATCC strains were used as quality control of both identification and sensitivity testing.

Statistical Analysis: All of the data was entered and analyzed using IBM SPSS statistics version 26.

#### RESULT

A total of 220 urine samples were processed in microbiology laboratory tests. Of which a total of 150 samples showed significant bacteriuria. A total 0f 48 individuals were found to be diabetic after surveying their HbA1c levels(having HbA1c level greater than 7). Of all 48 diabetic individuals 36 (75%) were found positive for UTI's, prevalence of UTI was more common in females in comparison to males in both diabetic and normal population(Table 4).

In this study of all 150 positive cultures, 135 (61.4%) gram negative and 12 (5.5%) gram positive bacteria were isolated, among which E.coli (52.7%) was the most common uropathogen followed by Klebsiella (25.3%), Pseudomonas (6.7%), Citrobacter (3.3%), Acinetobacter (2%) and Proteus (2%). Among the gram positive organisms, Enterococcus (5.3%) was the highest followed by Staphylococcus spp. (2.7%). Candida isolates were detected in 3 cases (2%). Table 5 & Table 6 are showing distribution and frequency of all the isolates identified during study.



Isolates of gram negative bacteria were more prevalent than gram positive bacteria in causing urinary tract infections. Among all GNB isolates E.coli from enterobacteriaceae family were the most common uropathogen in both diabetic and non-diabetic individuals(Table 4). The pattern of antibiotic sensitivity and resistance of the organisms were variable. E.coli being the most prevalent isolate showed most resistance to Azteronam, Ampicillin Sulbactam, Ceftriaxone and Cefuroxime (Table 7).

	Diabetic	Non-diabetic
No growth	12	58
Growth	36	114
Total	48	172

#### Table 2: Distribution of results from primary culture

#### Table 3: Gender based distribution of population

	Frequency	Percent
Male	101	45.9
Female	119	54.1
Total	220	100.0




Fig 2: Prevalence of UTI cases in diabetic population




Fig 3: Prevalence of UTI cases in non-diabetic population



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

#### Table 4: Primary distribution of isolates obtained from reading culture plates.

	diabetic		Non-diabetic	
	Male	Female	Male	Female
No growth	8	4	24	34
Gram-positive	1	1	6	4
Gram-negative	13	21	48	53
Byc	0	0	1	2

#### Table 5: Distribution of Isolates identified from all cultures

	Male		Female	
	diabetic	Non-diabetic	diabetic	Non-diabetic
No growth	8	24	4	34
E.coli	8	29	13	29
Klebsiella	3	12	4	16
Enterococcus faecalis	1	3	1	3
Pseudomonas aeruginosa	0	4	2	4
Citrobacter ferndii	0	3	1	1
Proteus mirabilis	0	0	1	2
Candida albicans	0	1	0	2
Acinetobacter	2	0	0	1
Staphylococcus	0	3	0	1
saprophyticus				

#### Table 6: Distribution of organisms causing UTI

Distribution of Organism					
	Frequency	Percent			
E.coli	79	52.7			
Klebsiella	35	23.3			
Enterococcus faecalis	8	5.3			
Pseudomonas aeruginosa	10	6.7			
Citrobacter ferndii	5	3.3			
Proteus mirabilis	3	2.0			
Candida albicans	3	2.0			
Acinetobacter	3	2.0			
Staphylococcus	4	2.7			
saprophyticus					
Total	150	100.0			






Fig 4: Distribution of isolates in UTI

#### Antibiotic resistance pattern

The susceptibility testing of Gram-negative bacteria was done for a total of 25 antibiotics included in AST-GN 405 card and overall results are summarized in Table 7. Overall resistance pattern of GNB isolates was graphically represented in Fig 5. Meropenem (87.6%) was the most susceptible antibiotic for gram negative bacilli followed by Netilmycin (87.6%), Imipenem (82.5%), Amikacin (82%) and Fosfomycin (81%).

The susceptibility testing of Gram-positive bacteria done for the 20 antibiotics included in AST-GP 628 card and overall results are summarized in Table 8. Overall resistance pattern of GPC isolates was graphically represented in Fig 6. For the gram positive organisms Imipenem, Nitrofurantoin, Gentamicin, Vancomycin and Linezolid were all found to be highly susceptible antibiotics followed by Ciprofloxacin, Rifampin.

Overall for gram positive organisms Ampicillin, Ampicillin sulbactam, Ticarcillin clavulanic, Minocycline showed high resistance rates and are not suitable to prescribe for treatment of UTIs without proper sensitivity testing (Fig 6). And for the gram negative organisms Ciprofloxacin, Ampicillin sulbactam, Doxycycline were found to be highly resistant (Fig 5).

	Organism						
							Proteus
Antibiotics		E.col	Klebsiell	Pseudomona	Acinetobacte	Citrobacte	mirabili
		i	a	s aeruginosa	r	r ferndii	S
Amikacin	RESISTANT	12	5	3	1	2	0
	SENSITIVE	63	28	7	3	3	3
	MODERATEL	5	2	0	0	0	0
	Y SENSITIVE						
Augmentin	RESISTANT	28	13	5	3	4	2

 Table 7: Sensitivity testing of all Gram negative isolates



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

	SENSITIVE	38	14	5	1	1	1
	MODERATEL	14	8	0	0	0	0
	Y SENSITIVE						
Aztreonam	RESISTANT	42	21	5	3	4	2
	SENSITIVE	38	14	5	1	1	1
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Ampicillin-	RESISTANT	42	21	5	3	4	2
Sulbactam							
	SENSITIVE	38	14	5	1	1	1
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Cefepime	RESISTANT	28	13	5	3	4	2
	SENSITIVE	52	22	5	1	1	1
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Cefoperazone	RESISTANT	31	16	3	1	2	0
Sulbactam							
	SENSITIVE	49	19	7	3	3	3
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Cefepime-	RESISTANT	27	13	3	1	2	0
Tazobactam							
	SENSITIVE	47	19	5	1	1	1
	MODERATEL	6	3	2	2	2	2
	Y SENSITIVE						
Ceftriaxone	RESISTANT	38	19	6	3	4	2
	SENSITIVE	42	16	4	1	1	1
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Cefuroxime	RESISTANT	38	20	6	3	4	2
	SENSITIVE	42	15	4	1	1	1
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Ciprofloxacin	RESISTANT	45	23	7	3	4	2
	SENSITIVE	21	9	3	1	1	1
	MODERATEL	14	3	0	0	0	0
	Y SENSITIVE						
Doripenem	RESISTANT	19	11	1	0	0	0
	SENSITIVE	56	22	9	4	5	3
	MODERATEL	5	2	0	0	0	0



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

	Y SENSITIVE						
Doxycycline	RESISTANT	37	19	5	1	1	1
	SENSITIVE	38	14	5	3	4	2
	MODERATEL	5	2	0	0	0	0
	Y SENSITIVE						
Ticareillin-	RESISTANT	31	18	4	2	2	2
Clavuanic							
	SENSITIVE	37	13	4	1	1	1
	MODERATEL	12	4	2	1	2	0
	Y SENSITIVE						
Gentamicin	RESISTANT	22	10	3	1	2	0
	SENSITIVE	58	25	7	3	3	3
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Imipenem	RESISTANT	15	8	1	0	0	0
	SENSITIVE	65	27	9	4	5	3
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Ertapenem	RESISTANT	10	6	1	0	0	0
	SENSITIVE	58	24	7	3	3	3
	MODERATEL	12	5	2	1	2	0
	Y SENSITIVE						
Co-	RESISTANT	21	12	2	0	0	0
Trimoxazole							
	SENSITIVE	59	23	8	4	5	3
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Levofloxacin	RESISTANT	30	18	2	0	0	0
	SENSITIVE	31	12	8	4	5	3
	MODERATEL	19	5	0	0	0	0
	Y SENSITIVE						
MInocycline	RESISTANT	20	10	3	1	1	1
	SENSITIVE	55	23	7	3	4	2
	MODERATEL	5	2	0	0	0	0
	Y SENSITIVE						
Meropenem	RESISTANT	10	6	1	0	0	0
	SENSITIVE	70	29	9	4	5	3
	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Netilmicin	RESISTANT	10	6	1	0	0	0
	SENSITIVE	70	29	9	4	5	3



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

	MODERATEL	0	0	0	0	0	0
	Y SENSITIVE						
Nitrofurantoi	RESISTANT	5	3	1	0	0	0
n							
	SENSITIVE	52	22	6	3	3	3
	MODERATEL	23	10	3	1	2	0
	Y SENSITIVE						
Piperacillin-	RESISTANT	37	19	4	1	2	0
Tazobactam							
	SENSITIVE	38	13	6	3	3	3
	MODERATEL	5	3	0	0	0	0
	Y SENSITIVE						
Fosfomycin	RESISTANT	19	6	1	0	0	0
	SENSITIVE	61	29	9	4	5	3
Colistin	RESISTANT	35	15	4	1	1	1
	SENSITIVE	11	3	0	0	0	0
	MODERATEL	34	17	6	3	4	2
	Y SENSITIVE						




Fig 5: Overall Resistance patterns of Gram negative organisms



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

		GPC	
Antibiotics		Enterococcus	Staphylococcus
		faecalis	saprophyticus
Ampicillin	RESISTANT	3	1
	SENSITIVE	3	2
	MODERATELY	2	1
	SENSITIVE		
Augmentin	RESISTANT	0	1
	SENSITIVE	6	2
	MODERATELY	2	1
	SENSITIVE		
Amoxicillin	RESISTANT	1	0
	SENSITIVE	6	4
	MODERATELY	1	0
	SENSITIVE		
Ciprofloxacin	RESISTANT	0	0
	SENSITIVE	7	2
	MODERATELY	1	2
	SENSITIVE		
Rifampicin	RESISTANT	0	0
	SENSITIVE	7	4
	MODERATELY	1	0
	SENSITIVE		
Doxycycline	RESISTANT	2	0
	SENSITIVE	5	3
	MODERATELY	1	1
	SENSITIVE		
Teicoplanin	RESISTANT	1	1
	SENSITIVE	4	1
	MODERATELY	3	2
	SENSITIVE		
Ticarcillin Clavulanic	RESISTANT	2	1
	SENSITIVE	6	2
	MODERATELY	0	1
	SENSITIVE		
Gentamicin	RESISTANT	0	0
	SENSITIVE	7	4
	MODERATELY	1	0
	SENSITIVE		
Imipenem	RESISTANT	0	0

#### Table 8: Sensitivity testing of all Gram positive isolates



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

	SENSITIVE	8	4
	MODERATELY	0	0
	SENSITIVE		
Levofloxacin	RESISTANT	0	0
	SENSITIVE	7	3
	MODERATELY	1	1
	SENSITIVE		
Minocycline	RESISTANT	2	1
	SENSITIVE	4	3
	MODERATELY	2	0
	SENSITIVE		
Nitrofurantoin	RESISTANT	0	0
	SENSITIVE	6	3
	MODERATELY	2	1
	SENSITIVE		
Daptomycine	RESISTANT	2	0
	SENSITIVE	3	4
	MODERATELY	3	0
	SENSITIVE		
Penicillin	RESISTANT	2	1
	SENSITIVE	5	3
	MODERATELY	1	0
	SENSITIVE		
Vancomycin	RESISTANT	0	0
	SENSITIVE	7	3
	MODERATELY	1	1
	SENSITIVE		
Linezolid	RESISTANT	1	0
	SENSITIVE	5	4
	MODERATELY	2	0
	SENSITIVE		
Piperacillintazobactam	RESISTANT	0	2
	SENSITIVE	7	2
	MODERATELY	1	0
	SENSITIVE		
Tetracycline	RESISTANT	1	2
	SENSITIVE	4	1
	MODERATELY	3	1
	SENSITIVE		

E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com




Fig 6: Overall Resistance patterns of Gram positive organisms

#### DISCUSSION

UTIs are one of the most common infections diagnosed worldwide. However, with the emergence of antibiotic resistant bacteria the management of UTIs has become more difficult with common empirical antibiotics[2,5,26]. And employing resistant antibiotics for management of UTIs also adds to the increase in the prevalence of multidrug resistant bacterial isolates[16,24].

In this study we tried to determine whether there are differences in the etiology of UTI causing bacteria and in the antibiotic sensitivity patterns of the uropathogens causing UTI in diabetic and non-diabetic patients[7].

In this study out of the 48 diabetic individuals 36 individuals about 75% showed significant bacteriuria (Table 2)(Fig 2). Diabetic individuals showed greater than prevalence of UTI in non-diabetic individuals, 66.3% of all non-diabetic individuals showed significant bacteriuria (Fig 3). In this study it is observed that both gram negative and gram positive bacterias can cause UTI with different percentages (Table 4). Samples with a colony count of 10<sup>5</sup> CFU/ml were considered confirmed cases of UTI and were considered for identification and susceptibility testing.

Like most of recent studies, it is evident that prevalence of gram-negative bacteria causing UTI is much greater than gram-positive (Table 4). Among all GNB isolates obtained in current study E.coli is the most common pathogen responsible for causing urinary infections which is the same for all related recent studies[1,3,7,16,26] (Fig4).

There are few indications to treat UTIs, but employing inappropriate antibiotics without knowing etiology of pathogens for treatment is a major contributor to the development of multidrug resistance among uropathogens[7,15,25]. So, it is necessary to keep on monitoring the resistance pattern of different isolates in the population to avoid development of resistance of bacteria.



#### Limitation of the study

Since this study used a hospital- based non-probability random sampling method, there's a possible bias that hinders the generalization of the results to all DM patients in the community. Study has no data regarding the degree of glycemic control and type of diabetes.

The lack of clinical information to confirm the source of infection, as to whether the UTI cases in this study were hospital or community-acquired. And whether the individual has contracted symptomatic or asymptomatic bacteriuria were the major limitations of the present study.

#### CONCLUSION

In this study out of the 48 diabetic individuals 36 individuals about 75% showed significant bacteriuria (Table 2)(Fig 2), which is greater than prevalence of UTI in the normal population. E.coli isolates were the most common pathogen responsible for causing UTIs in both diabetic and non-diabetic populations. Antibiotics like meropenem, imipenem, amikacin and fosfomycin are found to be the most sensitive and can be prescribed by physicians for treatment of complicated UTI. The isolates of bacterial uropathogens showed higher resistance rates for commonly used empirical antimicrobials.

In this study many bacterial isolates showed multidrug resistance (Fig 5)(Fig 6). So, the knowledge of resistance patterns of routinely isolated uropathogens in a particular region or hospital may provide better options to physicians regarding the use of empirical antibiotics for treatment of UTI. Hence, routine monitoring of antibiotic resistance patterns will help to avoid the indiscriminate use of antibiotics and prevent the further development of antimicrobial resistance and administer the proper treatment to manage UTIs.

#### **REFERENCE LIST**

- 1. Bitew A, Molalign T, Chanie M. Species distribution and antibiotic susceptibility profile of bacterial uropathogens among patients complaining urinary tract infections. BMC Infect Dis. 2017 Sep 29;17(1):654. doi: 10.1186/s12879-017-2743-8. PMID: 28962545; PMCID: PMC5622472.
- Eremenko R, Barmatz S, Lumelsky N, Colodner R, Strauss M, Alkan Y. Urinary Tract Infection in Outpatient Children and Adolescents: Risk Analysis of Antimicrobial Resistance. Isr Med Assoc J. 2020 Apr;22(4):236-240. PMID: 32286027.
- Pouladfar G, Basiratnia M, Anvarinejad M, Abbasi P, Amirmoezi F, Zare S. The antibiotic susceptibility patterns of uropathogens among children with urinary tract infection in Shiraz. Medicine (Baltimore). 2017 Sep;96(37):e7834. doi: 10.1097/MD.000000000007834. PMID: 28906365; PMCID: PMC5604634.
- 4. Nerurkar, Alka, Priti Solanky, and Shanta S. Naik. "Bacterial pathogens in urinary tract infection and antibiotic susceptibility pattern." *Journal of Pharmaceutical and Biomedical Sciences* 21.21 (2012).
- 5. Beyene G, Tsegaye W. Bacterial uropathogens in urinary tract infection and antibiotic susceptibility pattern in jimma university specialized hospital, southwest ethiopia. Ethiop J Health Sci. 2011 Jul;21(2):141-6. doi: 10.4314/ejhs.v21i2.69055. PMID: 22434993; PMCID: PMC3275859.
- Nigussie D, Amsalu A. Prevalence of uropathogen and their antibiotic resistance pattern among diabetic patients. Turk J Urol. 2017 Mar;43(1):85-92. doi: 10.5152/tud.2016.86155. Epub 2017 Jan 27. PMID: 28270957; PMCID: PMC5330274.



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

- Bonadio, M., Costarelli, S., Morelli, G. *et al.* The influence of diabetes mellitus on the spectrum of uropathogens and the antimicrobial resistance in elderly adult patients with urinary tract infection. *BMC Infect Dis* 6, 54 (2006).
- 8. Woldemariam, H.K., Geleta, D.A., Tulu, K.D. *et al.* Common uropathogens and their antibiotic susceptibility pattern among diabetic patients. *BMC Infect Dis* 19, 43 (2019).
- 9. BL Chaudhary, Charu Chandra, Snehanshu Shukla. Bacteriology of urinary tract infection and antibiotic susceptibility pattern among diabetic patients. Int. J. Bioassays, 2014, 3 (08), 3224-3227.
- 10. Ann Stapleton, Urinary tract infections in patients with diabetes, The American Journal of Medicine, Volume 113, Issue 1, Supplement 1, 2002, Pages 80-84, ISSN 0002-9343.
- 11. A. Ronald, E. Ludwig, Urinary tract infections in adults with diabetes, International Journal of Antimicrobial Agents, Volume 17, Issue 4, 2001, Pages 287-292, ISSN 0924-8579.
- 12. Reinhard Fünfstück, Lindsay E. Nicolle, Markolf Hanefeld, Kurt G. Nabera. Urinary tract infection in patients with diabetes mellitus. Clinical Nephrology, Vol.77 No. 1/2012 (40-48), ISSN 0301-0430.
- Aswani SM, Chandrashekar U, Shivashankara K, Pruthvi B. Clinical profile of urinary tract infections in diabetics and non-diabetics. Australas Med J. 2014 Jan 31;7(1):29-34. doi: 10.4066/AMJ.2014.1906.
- R Simkhada. Urinary tract infection and antibiotic sensitivity pattern among diabetics. Nepal Med Coll J 2013; 15(1): 1-4.
- Khoshnood S, Heidary M, Mirnejad R, Bahramian A, Sedighi M, Mirzaei H. Drug-resistant gramnegative uropathogens: A review. Biomed Pharmacother. 2017 Oct;94:982-994. doi: 10.1016/j.biopha.2017.08.006. Epub 2017 Aug 12. PMID: 28810536.
- 16. Nagendra L, Boro H, Mannar V. Bacterial Infections in Diabetes. Endotext [Internet]. 2022 Apr 5.
- 17. Hoepelman, Andy IM, Ruby Meiland, and Suzanne E. Geerlings. "Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus." International journal of antimicrobial agents 22 (2003): 35-43.
- 18. Kees J Gorter, Eelko Hak, Nicolaas PA Zuithoff, Andy IM Hoepelman, Guy EHM Rutten, Risk of recurrent acute lower urinary tract infections and prescription pattern of antibiotics in women with and without diabetes in primary care, Family Practice, Volume 27, Issue 4, August 2010, Pages 379–385.
- 19. Ali Al-Asoufi, Ali Khlaifat, Amjad Al Tarawneh, Khalid Alsharafa, Muhamad Al-Limoun and Khaled Khleifat, 2017. Bacterial Quality of Urinary Tract Infections in Diabetic and Non Diabetics of the Population of Ma'an Province, Jordan. Pakistan Journal of Biological Sciences, 20: 179-188.
- 20. Akash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020 Jul;202(5):953-965. doi: 10.1007/s00203-020-01818-x. Epub 2020 Feb 3. PMID: 32016521; PMCID: PMC7223138.
- 21. Bono MJ, Leslie SW, Reygaert WC. Urinary Tract Infection. 2022 Nov 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29261874.
- 22. Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus. J Infect Chemother. 2021 Aug;27(8):1131-1136. doi: 10.1016/j.jiac.2021.05.012. Epub 2021 May 20. PMID: 34024733.
- 23. Colgan R, Jaffe GA, Nicolle LE. Asymptomatic Bacteriuria. Am Fam Physician. 2020 Jul 15;102(2):99-104. PMID: 32667160.



- 24. Sylvia Knapp; Diabetes and Infection: Is There a Link? A Mini-Review. *Gerontology* 1 February 2013; 59 (2): 99–104.
- 25. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012 Mar;16 Suppl 1(Suppl1):S27-36. doi: 10.4103/2230-8210.94253. PMID: 22701840; PMCID: PMC3354930.
- 26. Dr. P. Sneka, & Dr. V. Mangayarkarasi. (2019). Bacterial pathogens causing UTI and their antibiotic sensitivity pattern: a study from a tertiary care hospital from South India. *Tropical Journal of Pathology and Microbiology*, 5(6), 379-385.
- 27. Somashekara SC, Deepalaxmi S, Jagannath N, Ramesh B, Laveesh MR, Govindadas D. Retrospective analysis of antibiotic resistance pattern to urinary pathogens in a Tertiary Care Hospital in South India. J Basic Clin Pharm. 2014 Sep;5(4):105-8.

#### **APPENDIX-I**

#### **Plagiarism check**

# Plagiarism check was done with PrepostSeo plagiarism checker.


nups://www.preposiseo.com/pia	
🛆 Refrence papers - Google Drive 🗙 🛛 📴 Dissertation-Draft.docx - Google 🗙 🗍 🖬 Research_Reference - Google Shi: 🗴 🦻 Plagi	iarism Checker - Free & Accu X + V - O X
← → C  ■ prepostseo.com/plagiarism-checker	🖻 🖈 🗖 🌒 :
Plagiarism Result	Share It 🦳 f 💆 in
INTRODUCTION Diabetes mellitus (DM) is a metabolic syndrome usually characterized by abnormally elevated levels of blood glucose. It is defined by deficiency of insulin secretion by	0% Plagiarized Content 100% Unique Content
pancreas or inability of the body to utilize insulin. Increasing prevalence of diabetes is an alarming situation throughout the world and is a serious health problem, in most developing countries. In many studies it is concluded that individuals with DM show	Check Grammar Make it Unique Download report
higher prevalence to many infectious diseases[6,7,,26]. Poor control over diabetes, impaired renal function and nonspecific or specific	0 matches [+] show all matches
immunity have not been shown to be substantial contributors to the increased occurrence of morbidity of UTI among patients with diabetes. Hyperglycemia by itself alone does not provide enough evidence to be causing predictable increase in	
uropathogens in individuals with DM.[11] Urinary tract infections (UTI) are the one of the most common infections after the	
infections of the respiratory tract. The symptoms of UTI may vary from mild           Textbook BSc Nursing Students           Authored by a subject expert and reviewed by the renowned academicians PAN India C	BS Publication
■ P Type here to search O 🛱 🖶 🏹 🚳	27°C Mostly cloudy 🔨 🖮 🌾 ENG 29-07-2023 🖵



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email

fmr.com • Email: editor@ijfmr.com

	LITERATURE REVIEW	Plagiarize	ad		
	Most of the research done in recent years conclude that there is clinical evidence	0% Plagianza Content	eu		
	pointing to the higher prevalence of infectious diseases like UTI's among individuals	100% Unique			
	with DM. Asymptomatic bacteriuria can be defined as presence of bacteria in the urine	Content			
	with absence of urinary infection symptoms, a common clinical finding that often warrants a decision about whether to initiate antimicrobial therapy. There are few	Check Grammar Make it Unique Downloa	d report		
	indications for treatment of asymptomatic bacteriuria with commonly used empirical		0 matches		
	drugs, but using inappropriate drugs for treatment contributes to the development of		0 materies		
	antimicrobial resistance[10,15].	[+] show all matches			
	From recent studies around the world, the resistance rate of various drugs is different				
	for different regions of the world which is suspected to be due to availability of some				
	drugs in certain regions. Since the use of empirical drugs is concerned with resistance				
	rates of uropathogens knowledge of resistance patterns is important to reduce the risk of further development of drug resistance bacteria. Resistance rate of 20 I he				
	considered an acceptable limit for use of empirical drugs for treatment of UTIs[3,13].				
	UTI is caused by both GNB & GPC. However, according to most studies, commonly				
_	encountered hacteria are Gram negative in which F. coli is found to be the most				×
	Type here to search O 🛱 💼 📻 💽 eres - Google Drive x 📴 Dissertation-Draft.docx - Google X 🕆 Research_Reference - Google Shi x 🍂 Plagia	rism Checker - Free & Acc: × +		01:41 AM 29-07-2023 —	5
rence pap C	pers - Google Drive 🗙 📄 Dissertation-Draft.docx - Google x 📑 Research_Reference - Google Shi x 🅅 Plagia	rism Checker - Free & Accu X +	₩ <i>M</i> ENG 2 ∨ E		
rence pap C	ers - Google Drive 🗙 📄 Dissertation-Draft.docx - Google 🗙 📑 Research_Reference - Google Shii 🗴 隆 Plagia 🔒 prepostseo.com/plagiarism-checker	rism Checker - Free & Accu 🗙 🕂	v بن میں		
rence pap C M S	eers - Google Drive X E Dissertation-Draft.docx - Google X Research_Reference - Google Shi X R Plagia prepostseo.com/plagiarism-checker IETHODOLOGY	rism Checker - Free & Accu × + 0% 100% Unique	v رومی میں میں میں میں میں میں میں میں میں م		
C C N S A	eers - Google Drive X 📑 Dissertation-Draft.docx - Google X 😭 Research_Reference - Google Shii X 隆 Plagia e prepostseo.com/plagiarism-checker METHODOLOGY tudy Type and Population	rism Checker - Free & Accu × + Plagia Conter	v رومی میں میں میں میں میں میں میں میں میں م		
ence pap C M S A fr	eres - Google Drive X 📄 Dissertation-Draft.docx - Google X 📑 Research_Reference - Google Sh: X 🎝 Plagia e prepostseo.com/plagiarism-checker METHODOLOGY tudy Type and Population . cross-sectional prospective study was carried out for 2 months in the year 2023,	rism Checker - Free & Acc. × + 0% Plagial Conter 100% Unique Conter	v رومی میں میں میں میں میں میں میں میں میں م		
ence pap C M S A fr ra S	eers - Google Drive X 📄 Dissertation-Draft.docx - Google X 😭 Research_Reference - Google Shi X 🎝 Plagia Prepostseo.com/plagiarism-checker METHODOLOGY tudy Type and Population . cross-sectional prospective study was carried out for 2 months in the year 2023, rom March to April 2023. Urine samples of a total 220 individuals were taken at andom from the Microbiology department and were analyzed for this study. creeening of diabetic individuals was done by taking measures of their glycosylated	rism Checker - Free & Acc. × + 0% Plagia Conter 100% Unique Conter	v Rized nt nt nt	<u>−</u> ★ □	
C C S A fr ra S S h	Arers - Google Drive X Dissertation-Draft.docx - Google X Research_Reference - Google Sh: X Research_Referen	rism Checker - Free & Acc. × + 0% Plagia Conter 100% Unique Conter	rized nt	<u>−</u> ★ □	
C C M S A A fr r r r s S h ic	Areas - Google Drive X 📄 Dissertation-Draft.docx - Google X 😭 Research_Reference - Google Shi X 🎝 Plagia Prepostseo.com/plagiarism-checker METHODOLOGY tudy Type and Population . cross-sectional prospective study was carried out for 2 months in the year 2023, rom March to April 2023. Urine samples of a total 220 individuals were taken at andom from the Microbiology department and were analyzed for this study. creeening of diabetic individuals was done by taking measures of their glycosylated emoglobin (HbA1c) levels. All samples were cultured to obtain isolates for lentification and sensitivity testing.	rism Checker - Free & Acc. × + 0% Plagia Conter 100% Unique Conter	v Rized nt nt nt	<u>−</u> ★ □	
ence pap C M S A fr ra S S h icc Ir	Arers - Google Drive x Dissertation-Draft.docx - Google x Research_Reference - Google Shi x R Plagia prepostseo.com/plagiarism-checker METHODOLOGY tudy Type and Population across-sectional prospective study was carried out for 2 months in the year 2023, from March to April 2023. Urine samples of a total 220 individuals were taken at andom from the Microbiology department and were analyzed for this study. creening of diabetic individuals was done by taking measures of their glycosylated emoglobin (HbA1c) levels. All samples were cultured to obtain isolates for dentification and sensitivity testing. Inclusion criteria:	rism Checker - Free & Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr	v Rized nt nt nt	<u>−</u> ★ □	
ence pap C M S A A fr ra s S h icc Irr s S	wers - Google Drive       X       Dissertation-Draft.docx - Google       X       Research_Reference - Google Sh: X <td>rism Checker - Free &amp; Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr</td> <td>v Rized nt nt nt</td> <td><u>−</u> ★ □</td> <td></td>	rism Checker - Free & Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr	v Rized nt nt nt	<u>−</u> ★ □	
C C M S A fr r r r s S h i c Ir s Ir	Press - Google Drive x    Dissertation-Draft.docx - Google x	rism Checker - Free & Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr	v Rized nt nt nt	<u>−</u> ★ □	
rence pape C M S A A frr rat S S h icc Irr S Irr irr	Press - Google Drive × Dissertation-Draft.docx - Google × Plagia prepostseo.com/plagiarism-checker METHODOLOGY tudy Type and Population a cross-sectional prospective study was carried out for 2 months in the year 2023, room March to April 2023. Urine samples of a total 220 individuals were taken at andom from the Microbiology department and were analyzed for this study. creening of diabetic individuals was done by taking measures of their glycosylated emoglobin (HbA1c) levels. All samples were cultured to obtain isolates for dentification and sensitivity testing. Inclusion criteria: amples from all patients with a presumptive case of UTI were included in the study. Individuals having HbA1c level of ≥ 7 were considered as diabetic. Of all 220 Individuals in study 48 (21.8%) were found diabetic of which there were 22 males and	rism Checker - Free & Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr	v Rized nt nt nt	<u>−</u> ★ □	
ence page C M S A fr rate S h icc Ir s Ir ir 2	wers - Google Drive       ×	rism Checker - Free & Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr	v Rized nt nt nt	<u>−</u> ★ □	
ence pape C M S A fr r r s S h icc Ir r r s S Ir r 2 Ir	Alers - Google Drive × Dissertation-Draft.docx - Google × Plagea prepostseo.com/plagiarism-checker METHODOLOGY tudy Type and Population a cross-sectional prospective study was carried out for 2 months in the year 2023, from March to April 2023. Urine samples of a total 220 individuals were taken at andom from the Microbiology department and were analyzed for this study. creening of diabetic individuals was done by taking measures of their glycosylated emoglobin (HbA1c) levels. All samples were cultured to obtain isolates for lentification and sensitivity testing. Inclusion criteria: amples from all patients with a presumptive case of UTI were included in the study. Individuals having HbA1c level of ≥ 7 were considered as diabetic. Of all 220 individuals in study 48 (21.8%) were found diabetic of which there were 22 males and 6 females.(As shown in table1). moculation of primary isolation culture media	rism Checker - Free & Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr	v Rized nt nt nt	<u>−</u> ★ □	
ence pape C M S A fr ra S A fr ra S N h icc Ir s Ir ir 2 Ir T	wers - Google Drive       ×	rism Checker - Free & Accu x + Plagia Conter 100% Unique Conter Check Grammar Make it Unique Dowr	v Rized nt nt nt	<u>−</u> ★ □	



	found to be diabetic after surveying their HbA1c levels(having HbA1c level greater than Che	eck Grammar Make it Unique Download report	
	7). Of all 48 diabetic individuals 36 (75%) were found positive for UTI's, prevalence of	0 matches	
	UTI was more common in females in comparison to males in both diabetic and normal	u matches	
	population(Table 4).	[+] show all matches	
	In this study of all 150 positive cultures, 135 (61.4%) gram negative and 12 (5.5%) gram		
	positive bacteria were isolated, among which E.coli (52.7%) was the most common		
	uropathogen followed by Klebsiella (25.3%), Pseudomonas (6.7 %), Citrobacter (3.3%),		
	Acinetobacter (2%) and Proteus (2%). Among the gram positive organisms,		
	Enterococcus (5.3%) was the highest followed by Staphylococcus spp. (2.7%).		
	Candida isolates were detected in 3 cases (2%). Table 5 & Table 6 are showing		
	distribution and frequency of all the isolates identified during study.		×
		() ×	
	Textbook BSc Nursing Students Authored by a subject expert and reviewed by the renowned academicians PAN India CBS Publication	Open	
<b>1</b> <i>P</i>	Type here to search O 🗮 🔒 📊 🔯 💽	27°C Mostly cloudy 🔨 📟 🌈 ENG 01:44 AM	$\Box$

#### **APPENDIX-II**

<u>File E</u> dit	View Data		Analyze <u>G</u> raphs <u>U</u> tilitie:	_	<u>W</u> indow	Help										
	<u> </u>													Vi	sible: 4 of 4	Va
	💰 Sex	Population	💑 Organism	💑 Туре	var	var	var	var	var	var	var	var	var	var	var	
1	Male	Non-diabetic	E.coli	Gram-nega												
2	Female	Non-diabetic	E.coli	Gram-nega												
3	Female	Non-diabetic	E.coli	Gram-nega												
4	Male	Non-diabetic	Klebsiella	Gram-nega												
5	Female	diabetic	E.coli	Gram-nega												
6	Female	diabetic	E.coli	Gram-nega												
7	Female	Non-diabetic	E.coli	Gram-nega												
8	Male	diabetic	Klebsiella	Gram-nega												
9	Female	diabetic	Pseudomonas aeruginosa	Gram-nega												
10	Female	Non-diabetic	Candida albicans	Byc												
11	Female	Non-diabetic	E.coli	Gram-nega												
12	Male	Non-diabetic	Klebsiella	Gram-nega												
13	Male	Non-diabetic	E.coli	Gram-nega												
14	Female	Non-diabetic	E.coli	Gram-nega												
15	Female	Non-diabetic	Enterococcus fecalis	Gram-posit												
16	Female	Non-diabetic	E.coli	Gram-nega												
17	Male	Non-diabetic	Candida albicans	Byc												
18	Male	Non-diabetic	E.coli	Gram-nega												
19	Female	Non-diabetic		Gram-nega												
20	Female	diabetic		Gram-nega												
21	Female	Non-diabetic	Enterococcus fecalis													
22	Female	diabetic		Gram-nega												
23	Female	Non-diabetic	Klebsiella	Gram-nega												
	4											1000	_			1
Data View V	ariable View															

٥ \_

×

:



E-ISSN: 2582-2160 • Website: www.ijfmr.com

- Email: editor@ijfmr.com

Edit	View Data	Transform An	alyze <u>G</u> raphs <u>U</u> tilities		Window	Help										
	λ	uund												Vis	sible: 4 of 4 Va	ariat
	💰 Sex	💑 Population	💑 Organism	💑 Туре	var	var	var	var	var	var	var	var	var	var	var	
205	Male	Non-diabetic	No growth	No growth												
206	Female	Non-diabetic	No growth	No growth												
207	Female	Non-diabetic	No growth	No growth												
208	Female	Non-diabetic	No growth	No growth												
209	Male	diabetic	No growth	No growth												
210	Female	Non-diabetic	No growth	No growth												
211	Male	diabetic	No growth	No growth												
212	Female	Non-diabetic	No growth	No growth												
213	Male	Non-diabetic	No growth	No growth												
214	Female	Non-diabetic	No growth	No growth												
215	Female	Non-diabetic	No growth	No growth												
216	Female	Non-diabetic	No growth	No growth												
217	Male	diabetic	No growth	No growth												
218	Male	Non-diabetic	No growth	No growth												
219	Male	Non-diabetic	No growth	No growth												
220	Male	Non-diabetic	No growth	No growth												
221																
222																
223																
224																
225																
226																
227																
	4															)
a View	/ariable View															
										IBN	SPSS Statist	ics Processor	is ready	Unicode	ON	

<u>File Edit V</u>	GPC	Analyze		ľ	nsions <u>W</u> ind	dow <u>H</u> elp									
	GPC														
		Ampicillin	o Augmenti					1							
		🗞 Ampicillin	🙍 Augmenti											Visible: 21 of	21 Variable
	<b>F</b> 1 <b>F</b> 1		•• n	Amoxycill in	Ampicillin Sulbacta m	Ciprofloxa cin	🗞 Rifapicin	Doxycycli ne	💰 Telcoplani n	ricarcillin clavulanic	Sentamic in	🗞 Imipenam	💰 Levofloxa cin	💰 Minocycli ne	Nitrofu &
1	Enterococcus fecalis	SENSITIVE	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	RESISTANT	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	RESISTANT	SENSITI
2	Enterococcus fecalis	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	RESISTANT	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITI
3	Enterococcus fecalis	RESISTANT	SENSITIVE	MODERAT	RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	MODERAT	SENSITI
4	Enterococcus fecalis	MODERAT	MODERAT	SENSITIVE	SENSITIVE	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	MODERA
5	Enterococcus fecalis	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	MODERAT	SENSITI
6	Enterococcus fecalis	RESISTANT	MODERAT	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	MODERAT	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITI
7	Enterococcus fecalis	RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	RESISTANT	MODERA
8	Enterococcus fecalis	SENSITIVE	SENSITIVE	SENSITIVE	RESISTANT	SENSITIVE	MODERAT	SENSITIVE	RESISTANT	SENSITIVE	MODERAT	SENSITIVE	MODERAT	SENSITIVE	SENSITI
9 S	Staphylococcus sap	RESISTANT	SENSITIVE	SENSITIVE	RESISTANT	MODERAT	SENSITIVE	MODERAT	RESISTANT	MODERAT	SENSITIVE	SENSITIVE	MODERAT	RESISTANT	SENSITI
10 S	Staphylococcus sap	SENSITIVE	RESISTANT	SENSITIVE	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	MODERAT	RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITI
11 S	Staphylococcus sap	SENSITIVE	SENSITIVE			SENSITIVE	SENSITIVE	SENSITIVE	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITI
	Staphylococcus sap	MODERAT	MODERAT	SENSITIVE	SENSITIVE	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	MODERA
13															
14															
15															
16															
17															
18															
19															
20															
21															
1															•
Data View Va	riable View														
										IBM S	PSS Statistics I	Processor is re	adv	Jnicode:ON	
<b>ا ک</b>	Type here to search			0 1	it 💼	<b>.</b>	6			JIDM 0	~		/ ^ 📷 🧖	12:51	



E-ISSN: 2582-2160 • Website: www.ijfmr.com

•								0								
•						0								,	sible: 26 of 26	
	organism 🖒	💑 Amikacin	Augmenti n	Azterona m	Ampicillin	💑 Cefipime	Cefoperaz 🗞 onesulba		Ceftriaxo me	Cefuroxim e	Ciprofloxa	Doripene m	Doxycycli ne	Ticareillin Clavuanic	Sentamic in	ľ
					m		ctam	am								
_	E.coli E.coli					SENSITIVE	SENSITIVE		RESISTANT			SENSITIVE	RESISTANT	RESISTANT	SENSITIVE	-
_	E.coli					RESISTANT			RESISTANT			RESISTANT	RESISTANT	RESISTANT		-
_	E.coli	SENSITIVE				RESISTANT		MODERAT	RESISTANT			SENSITIVE	SENSITIVE	RESISTANT	SENSITIVE	-
	E.coli	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE		SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	
	E.coli	SENSITIVE				SENSITIVE			SENSITIVE		MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	-
_	E.coli E.coli	SENSITIVE				SENSITIVE			SENSITIVE		MODERAT RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE RESISTANT	-
_		MODERAT	RESISTANT			RESISTANT			RESISTANT	SENSITIVE		RESISTANT	RESISTANT	SENSITIVE	RESISTANT	-
	E.coli	RESISTANT	RESISTANT	RESISTANT	RESISTANT	RESISTANT	RESISTANT	RESISTANT	RESISTANT	RESISTANT	RESISTANT	SENSITIVE	SENSITIVE	MODERAT	RESISTANT	
	E.coli		MODERAT	RESISTANT		SENSITIVE			SENSITIVE					MODERAT	SENSITIVE	
	E.coli		MODERAT	RESISTANT		SENSITIVE			RESISTANT		SENSITIVE	RESISTANT	RESISTANT	RESISTANT	SENSITIVE	-
_	E.coli E.coli		MODERAT SENSITIVE	RESISTANT SENSITIVE		SENSITIVE SENSITIVE			SENSITIVE			SENSITIVE SENSITIVE	RESISTANT	RESISTANT	SENSITIVE	-
_	E.coli					SENSITIVE			RESISTANT			SENSITIVE	RESISTANT	RESISTANT	SENSITIVE	-
	E.coli	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	
	E.coli					RESISTANT			RESISTANT			RESISTANT	RESISTANT	RESISTANT	RESISTANT	-
	E.coli					RESISTANT	SENSITIVE		RESISTANT			SENSITIVE	SENSITIVE	RESISTANT	SENSITIVE	-
_	E.coli E.coli	SENSITIVE				SENSITIVE	SENSITIVE		SENSITIVE		SENSITIVE MODERAT	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	+
-	E.coli					SENSITIVE	SENSITIVE		SENSITIVE			SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	-
=	<b>T</b> 0	OFNOTIVE				DECICTANT					DECICTANT		OFNOITIVE		DECICTANT	
ew Va	riable View															
											IDM ODOO	Statistics Proc	and the second se	Unice	de:ON	
	Set2] - IBM SP ew <u>D</u> ata	SS Statistics Da		raphs <u>U</u> tilitie	es E <u>x</u> tension		Help								- 0	
				raphs <u>U</u> tilitie	es E <u>x</u> tension	is <u>W</u> indow	Help								_ 0	
dit <u>v</u>	ew Data	Iransform		raphs <u>U</u> tilitie	<b>P</b> H					1	]			,	isible: 26 of 26	
iit <u>v</u>	ew Data			Azterona	<b>P</b> H	Cefipime			Ceftriaxo me	Cefuroxim e	Ciprofloxa cin	Doripene m	Doxycycli ne	,	isible: 26 of 26	6 V
it <u>v</u>	ew <u>D</u> ata	Iransform	<u>Analyze G</u>	Azterona m	Ampicillin Sulbacta m	Cefipime	Cefoperaz	Cefepime Tazobact am	🀔 me	♥ e	• cin	• n	• ne	Clavuanic	isible: 26 of 26 Gentamic in	3 V
it V	ew Data	Iransform	Analyze <u>G</u>	Azterona m SENSITIVE	Ampicillin Sulbacta M SENSITIVE	Cefipime SENSITIVE	Cefoperaz onesulba ctam SENSITIVE	Cefepime Tazobact am SENSITIVE	me SENSITIVE	e SENSITIVE	Cin RESISTANT	SENSITIVE	RESISTANT	Clavuanic	isible: 26 of 26 Gentamic in SENSITIVE	5 V c
it ⊻	ew Data	Iransform	Analyze <u>G</u>	Azterona m SENSITIVE SENSITIVE	Ampicillin Sulbacta M SENSITIVE SENSITIVE	Cefipime SENSITIVE SENSITIVE	Cefoperaz onesulba ctam SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE	me SENSITIVE RESISTANT	e SENSITIVE RESISTANT	Cin RESISTANT RESISTANT	SENSITIVE SENSITIVE	RESISTANT RESISTANT	Clavuanic SENSITIVE RESISTANT	isible: 26 of 26 Gentami in SENSITIVE SENSITIVE	3 Vi C
it ⊻ P P P	ew Data	Iransform	Analyze <u>G</u> Augmenti n SENSITIVE SENSITIVE SENSITIVE	Azterona m SENSITIVE SENSITIVE SENSITIVE	Ampicillin Sulbacta m SENSITIVE SENSITIVE SENSITIVE	Cefipime SENSITIVE SENSITIVE SENSITIVE	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE	SENSITIVE RESISTANT SENSITIVE	e SENSITIVE RESISTANT SENSITIVE	Cin RESISTANT RESISTANT SENSITIVE	SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE	Clavuanic SENSITIVE RESISTANT SENSITIVE	isible: 26 of 26 Gentamin SENSITIVE SENSITIVE SENSITIVE	ic ( E E
it <u>V</u>	ew Data	Iransform	Analyze Q Augmenti n SENSITIVE SENSITIVE SENSITIVE RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT	Ampicillin Sulbacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE RESISTANT	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT	SENSITIVE RESISTANT SENSITIVE RESISTANT	e SENSITIVE RESISTANT SENSITIVE RESISTANT	cin RESISTANT RESISTANT SENSITIVE RESISTANT	SENSITIVE SENSITIVE SENSITIVE RESISTANT	RESISTANT RESISTANT SENSITIVE RESISTANT	ESISTANT RESISTANT RESISTANT	isible: 26 of 26 Gentamin SENSITIVE SENSITIVE SENSITIVE RESISTAN	SV C E E T
it <u>v</u>	ew Data	Iransform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT	Ampicillin Sulbacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE RESISTANT RESISTANT	Cefoperaz ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT	me SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	M m SENSITIVE SENSITIVE RESISTANT SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE	Ticareillin Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT	isible: 26 of 26 Gentamin SENSITIVE SENSITIVE RESISTAN SENSITIVE	S V: E E E T E
it <u>V</u> P P P P P	ew Data	Transform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT	Azterona Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT	Ampicillin Sulbacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT	Cefoperaz Cefoperaz Censulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE RESISTANT	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT	Me me SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	M m SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE	Ticareillin Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT MODERAT	isible: 26 of 26 Gentamin SENSITIVE SENSITIVE SENSITIVE RESISTAN RESISTAN	SV C E E T E T
it <u>V</u> P P P P P P P P	ew Data	Transform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT	Ampicillin Subacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT	Cefoperaz o onesulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE RESISTANT SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT	Me SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	M m SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE	Ticareillin Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SESISTAN SENSITIVE RESISTAN SENSITIVE SENSITIVE	SV C E E T E T E
P P P P P P A A A	ew Data	Transform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE	Azterona m SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE	Ampicillin Subacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT SENSITIVE	me SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE	E SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE	M m SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE RESISTANT	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT MODERAT RESISTANT SENSITIVE	SENSITIVE SENSITIVE SENSITIVE RESISTAN SENSITIVE RESISTAN SENSITIVE SENSITIVE SENSITIVE SENSITIVE	S V: E E E T E E
it <u>V</u> P P P P P P P P A A A A	ew Data	Iransform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE	Azterona m SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	Ampicillin Subacta m SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT SENSITIVE MODERAT	me SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	E SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	M m SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE RESISTANT SENSITIVE	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT MODERAT RESISTANT SENSITIVE RESISTANT	SENSITIVE SENSITIVE SENSITIVE RESISTAN SENSITIVE RESISTAN SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	
t <u>V</u> P P P P P P A A A A	ew Data	Transform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Ampicillin Subacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT SENSITIVE MODERAT MODERAT	me SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE     RESISTANT     SENSITIVE     RESISTANT     RESISTANT     RESISTANT     RESISTANT     SENSITIVE     RESISTANT     RESISTANT     RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	m     sensitive	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT MODERAT RESISTANT SENSITIVE RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SESTAN SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	
it <u>V</u> P P P P P P P P A A A A A C C	ew Data	Iransform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	Ampicillin Subacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE RESISTANT MODERAT RESISTANT MODERAT MODERAT MODERAT	me SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	E SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT NODERAT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SESTAN SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	3 V C C E E E T E E E E E E E E E
it <u>V</u> P P P P P P P P P C C C C	ew Data	Transform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT RESISTANT MODERAT MODERAT RESISTANT	Me SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	e SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT MODERAT RESISTANT RESISTANT RESISTANT RESISTANT MODERAT	SENSITIVE SENSITIVE SENSITIVE SESTAN SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	C C C C C C C C C C C C C C C C C C C
t <u>v</u> P P P P P P P P C C C C C	ew Data	Transform	Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subacta m SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT RESISTANT MODERAT MODERAT RESISTANT RESISTANT	The sensitive sensitive sensitive sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT NODERAT RESISTANT RESISTANT RESISTANT RESISTANT NODERAT MODERAT	SENSITIVE SENSITIVE SENSITIVE SESTAN SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	C C C C C C C C C C C C C C C C C C C
t <u>V</u> PP PP PP PP PP C C C C C C C	ew Data	Transform	Analyze G Augmenti a Augmenti sensitive Sensitive Sensitive Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE	The sensitive sensitive sensitive sensitive resistant sensitive se	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE	cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT MODERAT RESISTANT RESISTANT RESISTANT RESISTANT MODERAT SENSITIVE	SENSITIVE SENSITIVE SENSITIVE SESTAN SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	3 V c c c c c c c c c c c c c c c c c c c
t V	ew Data	Transform	Analyze G Augmenti a Augmenti n SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT RESISTANT SENSITIVE MODERAT	The sensitive sensitive sensitive sensitive resistant sensitive resistant sensitive resistant resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuanic SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT MODERAT RESISTANT RESISTANT RESISTANT RESISTANT MODERAT SENSITIVE RESISTANT	ISIBLE 26 of 26 Gentamin SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	G C C C C C C C C C C C C C C C C C C C
t Y	ew Data	Transform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m Sensitive Sensitive Resistant	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE MODERAT MODERAT MODERAT	The sensitive sensitive sensitive sensitive sensitive resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuaric SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE	3 V C C E E E E E E E E E E E E E E E E E
it Y	ew Data	Transform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m Sensitive Sensitive Resistant	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE MODERAT MODERAT MODERAT	The sensitive sensitive sensitive sensitive sensitive resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuaric SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE	
it Y	ew Data	Transform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m Sensitive Sensitive Resistant	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE MODERAT MODERAT MODERAT	The sensitive sensitive sensitive sensitive sensitive resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuaric SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE	
it Y	ew Data	Transform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m Sensitive Sensitive Resistant	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE MODERAT MODERAT MODERAT	The sensitive sensitive sensitive sensitive sensitive resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuaric SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE	
it Y	ew Data	Transform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m Sensitive Sensitive Resistant	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE MODERAT MODERAT MODERAT	The sensitive sensitive sensitive sensitive sensitive resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuaric SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE	
t V	ew Data	Transform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m Sensitive Sensitive Resistant	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE MODERAT MODERAT MODERAT	The sensitive sensitive sensitive sensitive sensitive resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuaric SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE	
t V	ew Data	Transform	Analyze G Augmenti n SENSITIVE SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Azterona m SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Ampicillin Subbacta m Sensitive Sensitive Resistant	Cefipime SENSITIVE SENSITIVE SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	Cefoperaz onesulba ctam SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Cefepime Tazobact am SENSITIVE SENSITIVE SENSITIVE RESISTANT MODERAT MODERAT MODERAT RESISTANT RESISTANT SENSITIVE MODERAT MODERAT MODERAT	The sensitive sensitive sensitive sensitive sensitive resistant sensitive resistant re	e SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT	Cin RESISTANT RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	RESISTANT RESISTANT SENSITIVE RESISTANT SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE SENSITIVE	Clavuaric SENSITIVE RESISTANT SENSITIVE RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT RESISTANT	SENSITIVE SENSITIVE	



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

201	yew D	da Transform	Analyze Graphs UNITIES Extension	ni <u>W</u> iedow	END														inter Gripts Utilities												
		🗓 🖛 r	• 🖹 📥 🗐 📭 M		1	۵ 💽											🔒 🔟	5 3	- Mi 📥 🗐 🛛	P 11		1.A	ی 📀								
														Visible: 4	of 4 Variables															Mai	ible: 4 of 4
	💰 Se	Population	📣 Organism 🛛 📣 Type	Ver	VBF	VM	VM .	NOT .	107	107	107	107	NOT.		or i		💰 Sex	Population	🚓 Organism	🚓 Туре	107	V0C	VIC	VIC	Var	Var	Ver	VM	Ver	107	101
		ile Non-diabetic	E.col Gram-regal												<u>_</u>	205		Non-diabetic	No growth												
		ile Non-diabetic	E.coli Gram-nega													296	Female	Non-diabetic		No growth											
	Fer	ile Non-diabetic	E.coli Graminega.													207	Fenale	Non-diabetic	No growth	No gravith											
	N	ile Non-clabetic	Klebsiella Gram-nega.													200	Fenale	Non-diabetic	No growth	No gravith											
	Ferr	ile dabetic	E.col Gran-rega													222	Male	dabetic	No growth	No growth											
	Fer	ile diabetic	E.col Grammega													210	Ferale	Non-dabetic	No growth	No growth											
	Fer	ile Non-diabetic	E.coli Gram-regal.													211	Male	diabetic	No growth	No growth											
	N	ile diabetic	Klabsiella Grammega.													212	Fenale	Non-diabetic	No growth	No growth											
	Fer	ile diabetic	Pseudomonas aeruginosa Gram-nega.													213	Male	Non-diabetic	No growth	No gravith											
	Fer	ile Non-diabetic	Candida albicans Dy													214	Ferale	Non-dabetic	No growth	No gravith											
	Terr	ile Non-clabetic	E.col Gtare-rega													215	Fergle	Non-clabetic	No growth	No growth											
	N	le Non-dabetic	Nebsiella Gran-rega.													216	Ferale	Non-clabetic	No growth	No growth											
	N	ile Non-diabetic	E.coli Gram-nega.													217	Male	diabetic	No growth	No growth											
	Fev	ile Non-diabetic	E.coli Gram-nega													218	Male	Non-diabetic	No greath	No gravity											
	Fer	ile Non-dabetic	Enterococcus fecalis Gran-posit													219	Male	Nos-dabetic	No greath	No gravith											
	Ferr	ile Non-clabetic	E.col Gran-nega													220	Male	Non-dabetic	No growth	No growth											
	N	ile Non-clabetic	Candida albicana By													221															
	N	ile Non-diabetic	E.col Gameega																												
	Ferr	ile Non-diabetic	E.coli Gram-rega																												
	Fex	ie dabetic	E.coli Graminega													224															
	Fer	ile Non-dabetic	Enterococcus fecalis Gram-posit													225															
	Ferr	ile dabetic	Kiebsiella Gran-rega													226															
	Fer	ile Non-clabetic	Kiebsiella Gran-rega												-	227															
												_	_	_	- P		1		CONTRACTOR OF STREET											_	_
iew.	anable We															Data View	Variable View														
										M CPOS SAME	Ins Processo	r Is ready	1 may	NO:0N												100	CPOS SNAM	os Processor	is ready	Unicode 2	-

		ett) - IBAA SPSS S										- a ×		ntoSet1) - IBM SPSS Statio													-	a
2.01					Bas Eglansion	a Wedow	EMb	-						Yew Data Evenal														_
3	I 🔒 🛙	📭 🖛 -	<b>- H</b>	<u>*</u> =	H M		-19	۲					i 🗃 🖬	🔒 🛄 🖬	· 📲 🎍	1 📥 🗐		h 📟	🔲 🖬	Pa 📀								
	Name	Type	Width	Decimals	Label	Values	Missing	Columna	Align	Measure	Role																Vable 21	a 21 W
1	Sex	Nameric	8	0		(1, Male)	Nore	8	All Flight	🚓 Nominal	> input			& GPC	A. Loreiriter	- Asserti	- Immerit	Invitie	- Centera	A Distancia	- Departe	<ul> <li>Telconteni</li> </ul>	- Tranitio	- Genterric	<ol> <li>Ininenam</li> </ol>	. Lerofoxa	<ul> <li>Mnocycl</li> </ul>	
2	Population	Nameric	8	0		(1, dabetic)	None	9	all Flight	🚓 Nominal	> input					•	• n	/ Subacta	cin		Derycych ne		clavulanic	• n		e cia	E 6	•
3	Organism	Namaric	10	0		grout)	Nore	17	編 PSgM	A Nominal	> input							m										
4	Тури	Nameric	8	2		(.00, No gro	Nore	8	邇 Fight	🚓 Nominal	> input		1	Enterococcus fecalis												SENSITIVE		
													2	Enterococcus fecalis												SENSITIVE		
													3	Enteroceccus fecalis							SENSITIVE I					SENSITIVE		- 51
													- 4	Enteroceccus fecalis				SENSITIVE I			SENSITIVE							
8													5	Enteroceccus fecalis	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	WODERAT	SE
													6	Enterococcus fecalis	RESISTANT	MODERAT	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	MODERAT	SENSITIVE	RESISTANT	SENSITIVE	SENSITIVE	SENSITIVE	SEVENNE	- 38
10													7	Enterococcus fecalis									RESISTANT			SENSITIVE		
													8	Enterococcus fecalis											SENSITIVE		SENSITIVE	
														Staphylococcus sap						SENSITIVE		RESISTANT		SENSITIVE			RESISTANT	
														Staphylococcus sap							SENSITIVE I					SENSITIVE		
14														Staphylecoccus sap												SENSITIVE		
15														Staphylecoccus sap	MODERAT	MODERAT	SENSITIVE	SEVERATIVE I	MODERAT	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	SENSITIVE	NQ
16													13															
													14															
10													15															
19													16															
20													17															
													10															
													19															
													20															
24													21															
			_					_			_			1														
ta View 1	fariable View												Data View V	atable View						-								
										10	ISPES RANK	mark											ion s	POS SNASACI I	THE REAL PROPERTY IS NO.	atv 🗌 🗍	NOR ON	
	Type here t				O HI			-				dy ∧ € de DNG 1252.4M							<b>a</b>									